Alphamab Starts China Phase II/III Trial of PD-L1/CTLA-4 Bispecific
October 29, 2021 at 05:14 AM EDT
Suzhou Alphamab Oncology started a China Phase II/III trial of its PD-L1/CTLA-4 bispecific antibody in patients with NSCLC who progressed after an anti-PD-(L)1 treatment. In the Phase III part of the trial, Alphamab will recruit about 486 patients aimed at OS and PFS as co-primary endpoints. Alphamab developed KN046 itself. In the trial, KN046 will be combined with lenvatinib and compared to docetaxel. The BLA for envafolimab (KN035) has been accepted and granted Priority Review in China . More details.... Stock Symbol: (HK: 9966) Share this with colleagues: // //
